Multimodal AI biomarkers: from biology to patient stratification - ESMO Daily Reporter

The AI tools sitting unused in your business aren't a tech problem. They're a fit problem. You bought something that sounded smart. Nobody used it. Now you're $200/month wiser and no closer to result

The AI tools sitting unused in your business aren't a tech problem. They're a fit problem.

You bought something that sounded smart. Nobody used it. Now you're $200/month wiser and no closer to results. That's not failure — that's what happens when tools get sold before problems get defined.

Here's what medicine is quietly teaching business about AI right now.

Doctors are combining patient records, imaging, lab data, and clinical history to spot patterns no single data source could reveal alone. The breakthrough isn't the AI itself. It's knowing exactly which information to feed it — and why.

Your business works the same way. AI doesn't fail because it's bad. It fails because it gets pointed at the wrong problem with the wrong inputs.

The businesses winning with AI right now picked one specific bottleneck first. Not "all of operations." One thing. Time estimates. Customer responses. Inventory gaps. Something measurable, something painful, something small enough to prove the concept in 30 days.

Start there. Define the problem before you touch a tool.

What's the one repetitive task in your business that eats time every single week — and what have you already tried to solve it with?

#AIstrategy #BusinessGrowth #SmallBusiness #AIimplementation

Original Source

Artificial intelligence is enabling a new class of biomarkers by integrating histology, molecular data, imaging, and clinical records.